维昇药业-B(02561)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02561 维昇药业-B

休市中 07-25 16:08:06

49.000

+1.300

+2.73%

最高49.150	最低47.650	成交量3.83万
今开47.700	昨收47.700	日振幅3.14%
总市值55.86亿	流通市值55.86亿	总股本1.14亿
成交额186.27万	换手率0.03%	流通股本1.14亿
市净率21.15	ROE-57.66%	每股收益-1.95
52周最高69.150	52周最低39.250	市盈率-25.18
股息0.00	股息收益率0.00	ROA-29.52%

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02561","market":"HK","secType":"STK","nameCN":"维昇药业-B","latestPrice":49,"timestamp":1753430886099,"preClose":47.7,"halted":0,"volume":38300,"delay":0,"floatShares":113999999,"shares":113999999,"eps":-1.946273,"marketStatus":"休市中","change":1.3,"latestTime":"07-25 16:08:06","open":47.7,"high":49.15,"low":47.65,"amount":1862680,"amplitude":0.031447,"askPrice":49,"askSize":200,"bidPrice":48.95,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-1.946273,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753666200000},"marketStatusCode":7,"adr":0,"listingDate":1742486400000,"exchange":"SEHK","adjPreClose":47.7,"openAndCloseTimeList":[[1753407000000,1753416000000],[1753419600000,1753430400000]],"volumeRatio":0.27132332090035516,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02561","defaultTab":"news","newsList":[{"id":"2553372002","title":"维升药业-B07月22日主力净流出32.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2553372002","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553372002?lang=zh_cn&edition=full","pubTime":"2025-07-22 16:15","pubTimestamp":1753172143,"startTime":"0","endTime":"0","summary":"07月22日, 维升药业-B股价跌1.58%，报收46.80元，成交金额343.3万元，换手率0.06%，振幅3.79%，量比0.55。维升药业-B今日主力资金净流出32.9万元，上一交易日主力净流入196万元。该股近5个交易日上涨2.74%，主力资金累计净流入163.1万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入80.6万元，其中净流入天数为2日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722170216a45be5f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722170216a45be5f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2551137423","title":"维升药业-B(02561)携手安科生物 加速长效生长激素中国商业化进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2551137423","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551137423?lang=zh_cn&edition=full","pubTime":"2025-07-15 10:19","pubTimestamp":1752545983,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维升药业-B7月14日宣布与安科生物签订战略合作框架协议。在合作期限内，维升药业授权安科生物在中国境内特定区域内排他性独家推广隆培促生长素产品。维升药业与安科生物成功牵手，双方围绕隆培促生长素展开的业务也有望完善安科生物在生长激素方面的布局，实现全剂型覆盖，凭借维升药业创新助力冲击中国市场。该产品目前已在美国及欧洲获批上市，预计2025年内在中国获批，计划在2028年将实现本地化商业生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1317772.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0060","BK0070","BK0042","BK1161","300009","02561"],"gpt_icon":0},{"id":"2548513398","title":"生物药产业合力突围：一款新型长效激素的本土化落地样本","url":"https://stock-news.laohu8.com/highlight/detail?id=2548513398","media":"E药经理人","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548513398?lang=zh_cn&edition=full","pubTime":"2025-07-04 18:28","pubTimestamp":1751624921,"startTime":"0","endTime":"0","summary":"在生物药管线冲刺迈入“兑现期”前，如何将高技术壁垒的创新药物真正推向商业化，成为Biotech绕不开的现实大考。但当一部分Biotech挺进临床三期，站到商业化门槛时，一个现实的问题横亘在眼前：如何将创新项目合规、高效、高质量地推向规模化生产，完成从概念验证到商业化落地的完美闭环。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704183403a436c685&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704183403a436c685&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0417516902.SGD","LU0819121731.USD","BK1521","LU0516422952.EUR","SG9999002562.SGD","LU0181495838.USD","LU0823426480.USD","LU0327786744.USD","LU0979878070.USD","BK1576","LU1242518857.USD","SG9999002463.SGD","LU0348825331.USD","LU0326950275.SGD","BK1610","LU1688375341.USD","02561","LU0307460666.USD","LU0051755006.USD","LU0516422366.SGD","LU0456846285.SGD","LU0516422440.USD","LU0856984785.SGD","LU1242518931.SGD","LU1880383366.USD","LU2039709279.SGD","WXIBF","LU0823426308.USD","LU1794554557.SGD","02269","LU0516423174.USD","BK1141","LU0320764599.SGD","LU1720050803.USD","LU0140636845.USD","LU0359201612.USD","IE00B0JY6N72.USD","LU0708995583.HKD","LU0039217434.USD","LU0348735423.USD","LU0043850808.USD","LU0052750758.USD","LU0456827905.SGD","BK1589","LU0516423091.SGD","LU0572944931.SGD","LU0417516738.SGD","LU0588546209.SGD","LU0359202008.SGD"],"gpt_icon":0},{"id":"2548361593","title":"维升药业-B07月04日主力净流出32.2万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2548361593","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548361593?lang=zh_cn&edition=full","pubTime":"2025-07-04 16:15","pubTimestamp":1751616942,"startTime":"0","endTime":"0","summary":"07月04日, 维升药业-B股价跌1.19%，报收45.55元，成交金额132.1万元，换手率0.03%，振幅2.17%，量比0.85。维升药业-B今日主力资金净流出32.2万元，上一交易日主力净流出0万元。该股近5个交易日下跌4.21%，主力资金累计净流出108.0万元；近20日主力资金累计净流入242.7万元，其中净流入天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704170151a43691a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704170151a43691a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2546747356","title":"维升药业-B(02561)：选举付山继任董事会主席","url":"https://stock-news.laohu8.com/highlight/detail?id=2546747356","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546747356?lang=zh_cn&edition=full","pubTime":"2025-06-27 23:02","pubTimestamp":1751036525,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B 发布公告，Michael Wolff JENSEN先生及Jan Mller MIKKELSEN先生已于股东周年大会结束时退任。董事会进一步宣布，其已建议及选举付山先生继任董事会主席，自股东周年大会结束起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1311318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2546719685","title":"维升药业-B06月27日主力净流出29.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2546719685","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546719685?lang=zh_cn&edition=full","pubTime":"2025-06-27 16:15","pubTimestamp":1751012151,"startTime":"0","endTime":"0","summary":"06月27日, 维升药业-B股价跌2.00%，报收46.60元，成交金额250.0万元，换手率0.05%，振幅2.73%，量比1.77。维升药业-B今日主力资金净流出29.5万元，上一交易日主力净流出0万元。该股近5个交易日下跌4.31%，主力资金累计净流出3.9万元；近20日主力资金累计净流入350.6万元，其中净流入天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627173305a7208de5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627173305a7208de5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2544157782","title":"维升药业-B06月19日主力净流出27.7万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2544157782","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544157782?lang=zh_cn&edition=full","pubTime":"2025-06-19 16:15","pubTimestamp":1750320951,"startTime":"0","endTime":"0","summary":"06月19日, 维升药业-B股价跌3.45%，报收49.00元，成交金额320.1万元，换手率0.06%，振幅5.71%，量比0.46。维升药业-B今日主力资金净流出27.7万元，上一交易日主力净流入28.1万元。该股近5个交易日上涨1.55%，主力资金累计净流入325.2万元；近20日主力资金累计净流入199.9万元，其中净流入天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619174038a4b25192&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619174038a4b25192&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2544978997","title":"维升药业-B06月18日主力净流入28.1万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2544978997","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544978997?lang=zh_cn&edition=full","pubTime":"2025-06-18 16:15","pubTimestamp":1750234546,"startTime":"0","endTime":"0","summary":"06月18日, 维升药业-B股价涨2.01%，报收50.75元，成交金额291.7万元，换手率0.05%，振幅3.32%，量比0.42。维升药业-B今日主力资金净流入28.1万元，上一交易日主力净流出73.9万元。该股近5个交易日上涨7.98%，主力资金累计净流入352.9万元；近20日主力资金累计净流入275.0万元，其中净流入天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250618173908a71039ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250618173908a71039ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2544685549","title":"维升药业-B06月17日主力净流出73.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2544685549","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544685549?lang=zh_cn&edition=full","pubTime":"2025-06-17 16:15","pubTimestamp":1750148126,"startTime":"0","endTime":"0","summary":"06月17日, 维升药业-B股价跌7.53%，报收49.75元，成交金额942.4万元，换手率0.16%，振幅7.99%，量比1.60。维升药业-B今日主力资金净流出73.9万元，上一交易日主力净流入100.7万元。该股近5个交易日上涨3.22%，主力资金累计净流入324.8万元；近20日主力资金累计净流入299.8万元，其中净流入天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250617172843a4adfcbd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250617172843a4adfcbd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2543416623","title":"港股异动 | 维升药业-B(02561)涨超6% 隆培促生长素本地化生产进一步落实 那韦培肽新药申请获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2543416623","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543416623?lang=zh_cn&edition=full","pubTime":"2025-06-16 15:14","pubTimestamp":1750058044,"startTime":"0","endTime":"0","summary":"消息面上，6月9日，维升药业与药明生物宣布，维升药业核心产品隆培促生长素商业化批次的技术转移项目正式落地成都，双方还将在该基地合作建设国内首条双腔冻干制剂生产线，这一创新型药物制剂生产技术能极大地提升药物稳定性及临床使用便捷性。据悉，2023年12月，维升药业与药明生物已就隆培促生长素的技术转移首次达成战略合作。维升药业拥有那韦培肽在大中华区的独家开发、生产和商业化权利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1305615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2543681110","title":"医药生物IPO“港漂”热潮：三大热门创新药成焦点，恒瑞医药4个月便实现A+H","url":"https://stock-news.laohu8.com/highlight/detail?id=2543681110","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543681110?lang=zh_cn&edition=full","pubTime":"2025-06-13 19:50","pubTimestamp":1749815428,"startTime":"0","endTime":"0","summary":"部分企业“弃A转港”，或为这波港股医药生物IPO热潮添一把火。排队IPO企业方面，截至今年5月31日，港股医药生物IPO申报企业共有20家。医药生物企业扎堆赴港IPO，或与A股IPO审核趋严有关。未盈利医药生物企业扎堆赴港IPO，与港交所创新性推出的18A上市规则有关。例如，恒瑞医药、派格生物、觅瑞等均在招股书中明确提出“出海”计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613195043951b08b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613195043951b08b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02561","BK1574","06978","01276","BK1161","09606"],"gpt_icon":1},{"id":"2542511170","title":"维升药业的独立性与生长激素困局","url":"https://stock-news.laohu8.com/highlight/detail?id=2542511170","media":"市值观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542511170?lang=zh_cn&edition=full","pubTime":"2025-06-12 20:02","pubTimestamp":1749729766,"startTime":"0","endTime":"0","summary":"目前，维升药业旗下最重磅产品为隆培促生长素，已完成三期临床，其上市许可申请已于2024年3月获国家药监局受理，预计在2025年将获准上市。这足见维升药业上市的紧迫性。2023年12月，维升药业与药明生物签订协议，后者作为接收点参与大股东技术转移，最终完成隆培促生长素药物原液的本地商业化供应，预计于2028年实现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250612202416a4a52a9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250612202416a4a52a9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSCEI","HSTECH","02561","BK1161"],"gpt_icon":1},{"id":"2540453797","title":"维升药业-B盘中涨超6% 公司预计隆培促生长素于下半年在国内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2540453797","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540453797?lang=zh_cn&edition=full","pubTime":"2025-06-03 10:58","pubTimestamp":1748919501,"startTime":"0","endTime":"0","summary":"维升药业-b盘中涨超6%，截至发稿，涨5.95%，报47.2港元，成交额131.9万港元。该行续指，根据公司招股书，公司研发进展最快的是隆培促生长素，公司预计在2025H2国内获批上市；国内长效生长激素市场相对蓝海，弗若斯特沙利文预测有望在2030年达到211亿元，公司的产品优势明显，有望获得较大的市场分额。目前，公司拥有2款独特品种，分别为那韦培肽和帕罗培特立帕肽，后者有望在2025年底递交上市申请，一齐为公司的长期增长提供驱动力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603110447a6f7eb33&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603110447a6f7eb33&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2538429042","title":"维升药业-B05月28日主力净流出42.8万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2538429042","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538429042?lang=zh_cn&edition=full","pubTime":"2025-05-28 16:15","pubTimestamp":1748420116,"startTime":"0","endTime":"0","summary":"05月28日, 维升药业-B股价跌4.27%，报收44.80元，成交金额271.1万元，换手率0.05%，振幅4.27%，量比1.19。维升药业-B今日主力资金净流出42.8万元，上一交易日主力净流出0万元。该股近5个交易日下跌2.19%，主力资金累计净流出107.3万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出255.9万元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250528171932a6f02037&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250528171932a6f02037&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2538138654","title":"三家顶级投行一致推荐，维升药业-B(2561.HK)为何能够获资本共识？","url":"https://stock-news.laohu8.com/highlight/detail?id=2538138654","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538138654?lang=zh_cn&edition=full","pubTime":"2025-05-28 07:58","pubTimestamp":1748390286,"startTime":"0","endTime":"0","summary":"近一个月来，深耕内分泌治疗领域的维升药业持续在资本市场引发关注，先后获得了Morgan Stanley、Jefferies，以及中信证券三家机构“增持”及“买入”评级。价值低估的内分泌赛道黑马从三家机构给出的目标价来看，当前维升药业股价隐含显著低估空间，长期价值释放通道已逐渐清晰。目前，其上市许可申请已获国家药监局受理，预计将在今年下半年获批上市。国内尚无相关针对性药物获批，市场格局良好。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505280758139767b4b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505280758139767b4b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2538728521","title":"维升药业-B05月26日遭主力抛售69.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2538728521","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538728521?lang=zh_cn&edition=full","pubTime":"2025-05-26 16:15","pubTimestamp":1748247332,"startTime":"0","endTime":"0","summary":"05月26日, 维升药业-B股价跌3.26%，报收45.95元，成交金额166.9万元，换手率0.03%，振幅4.84%，量比0.68。维升药业-B今日主力资金净流出69.2万元，上一交易日主力净流出42.7万元。该股近5个交易日上涨4.43%，主力资金累计净流出11.7万元；近20日主力资金累计净流出334.3万元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250526172333a6ed5461&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250526172333a6ed5461&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2537991145","title":"维升药业-B05月22日获主力加仓47.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537991145","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537991145?lang=zh_cn&edition=full","pubTime":"2025-05-22 16:15","pubTimestamp":1747901747,"startTime":"0","endTime":"0","summary":"05月22日, 维升药业-B股价涨2.84%，报收47.05元，成交金额444.6万元，换手率0.08%，振幅8.42%，量比3.03。维升药业-B今日主力资金净流入47.4万元，上一交易日主力净流入52.8万元。该股近5个交易日上涨3.73%，主力资金累计净流入100.2万元；近20日主力资金累计净流入144.0万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250522173801a6e8a900&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250522173801a6e8a900&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2537985035","title":"维升药业-B05月21日主力净流入52.8万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2537985035","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537985035?lang=zh_cn&edition=full","pubTime":"2025-05-21 16:15","pubTimestamp":1747815356,"startTime":"0","endTime":"0","summary":"05月21日, 维升药业-B股价涨3.86%，报收45.75元，成交金额210.5万元，换手率0.04%，振幅4.77%，量比1.50。维升药业-B今日主力资金净流入52.8万元，上一交易日主力净流出0万元。该股近5个交易日下跌1.40%，主力资金累计净流入52.8万元；近20日主力资金累计净流入96.6万元，其中净流入天数为5日。该股主力净额占比0.01%，港股市场排名337/2645。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250521173203a6e737ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250521173203a6e737ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2535946327","title":"港股异动 | 维升药业-B(02561)涨超5% 治疗软骨发育不全药物那韦培肽完成中国2期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2535946327","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535946327?lang=zh_cn&edition=full","pubTime":"2025-05-13 14:54","pubTimestamp":1747119240,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维升药业-B涨超5%，截至发稿，涨5.39%，报46.9港元，成交额217.21万港元。消息面上，5月12日，维升药业宣布其在研的用于治疗软骨发育不全的那韦培肽中国2期临床试验已全部顺利完成，并于近期在国家药监局“药物临床试验登记与信息公示平台”登记临床试验结果信息。据悉，那韦培肽中国2期临床试验针对中国2至10岁ACH患儿，采用每周一次皮下给药的方式，旨在安全治疗剂量下持续提供活性CNP。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1292438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02561","BK1161","BK1576","BK1141","03347","BK1583"],"gpt_icon":0},{"id":"2534291132","title":"维升药业那韦培肽完成中国2期临床试验，用于治疗软骨发育不全","url":"https://stock-news.laohu8.com/highlight/detail?id=2534291132","media":"时代财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534291132?lang=zh_cn&edition=full","pubTime":"2025-05-12 18:55","pubTimestamp":1747047306,"startTime":"0","endTime":"0","summary":"本文来源：时代财经5月12日，维升药业宣布其在研的用于治疗软骨发育不全的那韦培肽中国 2 期临床试验已全部顺利完成，并于近期在国家药监局“药物临床试验登记与信息公示平台”登记临床试验结果信息。据维升药业介绍，那韦培肽中国2期临床试验针对中国2至10岁ACH患儿，采用每周一次皮下给药的方式，旨在安全治疗剂量下持续提供活性CNP。另据沙利文数据，2023年中国软骨发育不全的患病人数为5.12万例，其中可以治疗的儿童约1万例。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051219180797572666&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051219180797572666&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1583","BK1161","02561","03347","BK1141"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.visenpharma.com","stockEarnings":[{"period":"1week","weight":0.0273},{"period":"1month","weight":0.0316},{"period":"3month","weight":0.0251},{"period":"6month","weight":-0.2878},{"period":"ytd","weight":-0.2878}],"compareEarnings":[{"period":"1week","weight":0.0227},{"period":"1month","weight":0.0373},{"period":"3month","weight":0.155},{"period":"6month","weight":0.2652},{"period":"1year","weight":0.493},{"period":"ytd","weight":0.2656}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"维昇药业是一家主要从事开发并商业化颠覆式内分泌疗法的投资控股公司。该公司的主要在研产品包括隆培促生长素、那韦培肽和帕罗培特立帕肽。隆培促生長素用于治疗3至17岁儿童生长激素缺乏症患者。那韦培肽是一款用于治疗2至10岁软骨发育不全儿童患者的疾病修复疗法。帕罗培特立帕肽是一款用于治疗成人甲状旁腺功能减退症的治疗方法。该公司处于研发后期、产品接近商业化。","exchange":"SEHK","name":"维昇药业-B","nameEN":"VISEN PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维昇药业-B(02561)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维昇药业-B(02561)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维昇药业-B,02561,维昇药业-B股票,维昇药业-B股票老虎,维昇药业-B股票老虎国际,维昇药业-B行情,维昇药业-B股票行情,维昇药业-B股价,维昇药业-B股市,维昇药业-B股票价格,维昇药业-B股票交易,维昇药业-B股票购买,维昇药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维昇药业-B(02561)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维昇药业-B(02561)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}